Chronic Hepatitis Current Events

Chronic Hepatitis Current Events, Chronic Hepatitis News Articles.
Sort By: Most Viewed | Most Recent
Page 1 of 25 | 1000 Results
Public health-primary care testing has high uptake, doesn't identify hidden Hepatitis C
Public health-primary care testing has high uptake, doesn't identify hidden Hepatitis C. (2018-01-09)

No advantage of combination drug therapy for chronic hepatitis B Infection
Results of an international study in this week's issue of The Lancet suggest that pegylated interferon alpha offers the best treatment option for people with chronic hepatitis B infection. (2005-01-06)

Study finds racial differences in cure rates for Hepatitis C
In a large ethnically diverse group of patients seen at a community-based Veterans Affairs practice, cure rates for chronic hepatitis C were lower for African American individuals relative to White individuals, even when patients were receiving optimal therapies. The findings are published in Pharmacology Research & Perspectives. (2018-02-22)

Possible Dangers Of Taking Over-The-Counter Medications For Hepatitis C Patients
Patients with chronic hepatitis C often take the over-the- counter non-steroidal drug Ibuprofen, otherwise known as Motrin or Advil, to combat joint pain that often accompanies the disease. Even a low dose could lead to unsuspecting liver damage. (1998-09-16)

Acute Hepatitis A evades immune system more effectively than chronic cousin
Lemon and his colleagues thought that Hepatitis C might become chronic by disrupting the host's interferon response -- part of the innate immune system that protects the body against any kind of (2011-06-20)

Vaccinate infants of hepatitis B mothers, say experts
Immunising newborn infants of mothers with hepatitis B prevents infection being transmitted from mother to child, finds a study published online by the BMJ today. (2006-01-26)

Britain should adopt universal hepatitis B immunisation
Britain should adopt universal hepatitis B immunisation, says a senior doctor in this week's BMJ. (2004-11-04)

Could a popular HIV drug benefit hepatitis B patients?
Saint Louis University School of Medicine researchers are studying the effectiveness of a drug for patients with chronic hepatitis B that is currently used to treat HIV. (2006-05-03)

Genetic variation may increase risk of liver damage in patients with chronic hepatitis B
A new study has shown that genetic variation may increase the risk of severe liver damage in Caucasians with chronic hepatitis B infection. (2018-07-26)

A new player in the battle against hepatitis prevents inflammation and the death of liver cells
Scientists from the Flanders Interuniversity Institute for Biotechnology (VIB) have again achieved a breakthrough in research on hepatitis. The researchers, connected to Ghent University, have discovered the function of one of the most important proteins involved in hepatitis. Using a mouse model, they have shown that the protein prevents inflammation of the liver as well as the death of liver cells. This discovery can form the basis for the development of a new therapy in the battle against hepatitis in humans. (2005-09-01)

Universal infant hepatitis B immunization recommended
All countries should offer universal infant immunization for hepatitis B, write Dr. Christopher Mackie from McMaster University and co-authors in a public health analysis in CMAJ. (2009-01-19)

Who will recover spontaneously from hepatitis C virus infection
An eight-year study led by Dr. Sabine Mihm from from Georg-August-Universität has investigated 67 spontaneously recovered patients and found that co-infection by hepatitis B virus is associated with a higher possibility of self recovery. In addition, patients who self recovered usually have lower levels of HCV antibody. But on the other hand, the researchers also found that active iv drug users are less likely to self recover. (2007-08-29)

Time for Britain to adopt universal hepatitis B immunisation
It's time for Britain to adopt universal hepatitis B immunisation, say senior doctors in an editorial published online by the BMJ today. (2006-03-23)

The economic cost of advanced liver disease
Health care costs for hepatitis C patients with end-stage liver disease are nearly 2.5 times higher than those in the early stages, according to a Henry Ford Hospital study. Although infection with the hepatitis C virus increases health care costs overall, the specific impact of the disease's progressive severity on health care costs has previously not been well studied. (2011-11-07)

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma. They demonstrated that people infected with Hepatitis D have up to three times the risk of developing that particularly aggressive and often fatal liver cancer compared to those infected only with Hepatitis B. These results, to be read in the Journal of Hepatology, plead for systematic screening of Hepatitis D in patients with Hepatitis B. (2020-05-18)

New investigational vaccine to prevent hepatitis C tested for first time in humans
With an estimated 170 million people around the world already infected with hepatitis C, Saint Louis University is testing, for the first time in humans, an investigational vaccine that researchers hope will prevent infection with the virus. The successful development of such a vaccine would represent a major step in combating this growing health problem. (2003-11-17)

New treatment for hepatitis C
A statin drug used to lower cholesterol found to stop hepatitis C, especially in patients resistant to standard treatment. (2008-05-14)

Deaths from viral hepatitis surpasses HIV/AIDS as preventable cause of deaths in Australia
Deaths from viral Hepatitis B and C have surpassed HIV/AIDS in many countries, including Australia and in Western Europe, according to an analysis of the 2010 Global Burden of Disease study. (2014-04-16)

Annals of Internal Medicine tip sheet for April 29, 2014
The April 29, 2014, issue of Annals of Internal Medicine includes papers titled 'Measles outbreaks prompt concern about physician knowledge gaps' and 'Viral hepatitis remains a major health concern in the US.' (2014-04-28)

Hepatitis B and C may be linked to increased risk of Parkinson's disease
The viruses hepatitis B and C may both be associated with an increased risk of Parkinson's disease, according to a study published in the March 29, 2017, online issue of Neurology, the medical journal of the American Academy of Neurology. The hepatitis virus affects the liver. (2017-03-29)

Measures needed to reduce bloodborne infections in Irish prisons
There is an urgent need for increased infection control and harm reduction measures to reduce the transmission of hepatitis B and C viruses, and HIV in Irish prisons, concludes a study in this week's BMJ. (2001-11-22)

When acute hepatitis develops into chronic hepatitis
Hepatitis B is the most prevalent infectious disease in the world. It results in either an acute infection or, in rare cases, it can develop into a chronic disease. Researchers at the Helmholtz Center for Infection Research in Braunschweig have now examined the way in which the immune system reacts differently to both chronic and acute hepatitis B. (2009-02-16)

Hepatitis B does not increase risk for pancreatic cancer
A Henry Ford Hospital study found that hepatitis B does not increase the risk for pancreatic cancer -- and that only age is a contributing factor. The results contradict a previous study in 2008 that suggested a link between pancreatic cancer and previous hepatitis B infection. Hepatitis B is an inflammation of the liver caused by a viral infection. (2009-10-31)

Study examines long-term effectiveness of hepatitis A vaccination in children
In a follow-up study of children who were vaccinated against hepatitis A virus at ages 6 to 21 months, most children who were vaccinated at 12 or 15 months continued to have anti-hepatitis A antibodies in their blood until at least age 15 to 16 years, (2016-02-01)

New combination drug treatment for hepatitis C
Results of a randomised trial in this week's issue of THE LANCET suggest that the drug combination peginterferon alfa-2b and ribavirin offers the best therapeutic treatment for patients with chronic hepatitis C. (2001-09-20)

Hepatitis B continues to be a global health problem
Hepatitis B infections are among the most common infectious diseases worldwide. In the scope of an international study funded by the World Health Organization, scientists from the Helmholtz Centre for Infection Research in Braunschweig determined how often the chronic infection occurs in different countries and how many people of the general population are affected. They noted strong differences between different countries. Their results are published in the scientific journal, The Lancet. (2015-07-28)

Europe: Chronic hepatitis B infections on the rise since 2008
In 2017, the majority (58%) of the almost 27 000 newly reported hepatitis B cases in the European Union and European Economic Area were classified as chronic infections. This follows a consistent upward trend in reported chronic hepatitis B cases since 2008. (2019-06-20)

New study identifies genetic variant that could help reduce need for liver transplants
A new study from the Westmead Institute for Medical Research has identified a genetic variant associated with liver fibrosis (scarring) in chronic hepatitis C patients. This finding is a step toward reducing the number of patients requiring liver transplants. (2019-04-02)

Fibroleukin at fault in viral hepatitis
Acute and chronic liver disease caused by the hepatitis B virus results from fibrin deposition and thrombosis within the small blood vessels of the liver. In the July 1 issue of the JCI, Philip Marsden and colleagues from the University of Toronto show that mice lacking the prothrombinase Fgl2/fibroleukin fail to develop this response, suggesting a potential target in the treatment of inflammatory diseases not only of the liver but also of other tissues. (2003-07-01)

Liver damage in hepatitis C patients significantly underestimated, says Henry Ford study
The number of hepatitis C patients suffering from advanced liver damage may be grossly underestimated and underdiagnosed, according to a study led by researchers at Henry Ford Health System and the US Centers for Disease Control and Prevention. The findings were the result of a study of nearly 10,000 patients suffering from hepatitis C, and could have a significant effect on patient care and healthcare policy regarding the chronic disease. (2015-08-18)

Available treatments for hepatitis C virus cost-effective when initiated early
New treatments for hepatitis C virus (HCV) may be highly effective but are associated with substantial costs that may compel clinicians and patients to consider delaying treatment. However, a new study shows that immediate treatment of HCV-infected patients with moderate or advanced liver scarring is cost-effective. Immediate treatment of patients with minimal or no scarring can be cost-effective as well, particularly when lower treatment costs are assumed. (2015-03-16)

Rutgers scientists identify structure of virus that could lead to hepatitis C vaccine
Rutgers University scientists have determined the structure of a hepatitis C surface protein, a finding that could assist in the development of a vaccine to halt the spread of the the deadly disease that has infected 3.2 million Americans. (2014-02-19)

Is Europe ready to eliminate viral hepatitis?
Currently, Europe records around 57,000 newly diagnosed acute and chronic cases of hepatitis B and C each year. On top of that, an estimated 10 million Europeans are believed to suffer from chronic hepatitis B and C infection -- and most are unaware of the disease. In order to eliminate hepatitis as a public health issue, Europe needs to scale-up coverage of testing, prevention interventions and treatment services. (2016-07-27)

U.S. Healthcare Burden To Soar Unless Hepatitis C Detection, Treatment Improve
CHICAGO, November 9 -- A study made public for the first time at The American Association for the Study of Liver Diseases 1998 Annual Meeting in Chicago,November 6 - 10, predicts that the US could face a daunting health care burden from Hepatitis C virus (HCV) infection over the next decade. (1998-11-09)

New book on The Hepatitis B and Delta Viruses from CSHLPress
The Hepatitis B and Delta Viruses, from CSHLPress, examines all aspects of HBV and HDV infections and their management. Contributors discuss the HBV and HDV life cycles, their unique characteristics (e.g., the formation of HBV cccDNA), the immune responses they elicit, and the challenges they present to the development of antiviral treatments. The molecular mechanisms that lead to liver cirrhosis and hepatocellular carcinoma are reviewed, as are factors that influence the severity of the disease. Conventional treatments are also described. (2015-06-18)

Potential cure for hepatitis B enters phase 1/2a clinical trial
A new treatment developed by Walter and Eliza Hall Institute researchers to promote the cure of chronic hepatitis B virus infection is now recruiting patients for a phase I/2a clinical trial. (2014-12-14)

Donor kidneys from hepatitis C patients needlessly denied to patients with that infection
More than half of donor kidneys in the United State infected with hepatitis C are thrown away, despite the need among hepatitis C patients who may die waiting for an infection-free organ, Johns Hopkins research suggests. (2010-04-01)

Hepatitis B Foundation awards UT School of Public Health professor
R. Palmer Beasley, M.D., Ashbel Smith Professor at the University of Texas School of Public Health, has been awarded the Hepatitis B Foundation's Distinguished Scientist Award 2010. (2010-01-08)

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis. This is the result of a new study from Aarhus University. (2019-12-05)

Generic direct acting antivirals in treatment of chronic hepatitis C patients
There has been published results of the study 'ORIGINAL VERSUS GENERIC DIRECT ACTING ANTIVIRALS IN TREATMENT OF CHRONIC HEPATITIS C PATIENTS: REAL LIFE DATA FROM LATVIA' authored by Tolmane I, Rozentale B, Arutjunana S et al., recently. (2018-07-19)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to